Supplementary material to article by A. Gedebjerg et al. “IL-20, IL-21 and p40: Potential Biomarkers of Treatment Response for Ustekinumab”

Fig. S1. mRNA expression level in the responder group of various genes in lesional psoriatic skin (LS) during ustekinumab treatment. Punch biopsies from psoriatic patients treated with ustekinumab were collected. Total RNA was isolated and analysed by quantitative PCR (qPCR). Gene mRNA expression in non-lesional skin (NLS), lesional skin (LS), and in LS treated with ustekinumab for 4, 28 and 112 days is shown. mRNA expression was normalized to ribosomal protein, large, P0 (RPLP0). All samples were loaded as triplets. Results are presented by dot plots with the mean from 10 responders with psoriasis and each patient is represented by one symbol. *p<0.05, **p<0.01 and ***p<0.001 compared with LS at day 0.